He did not really answer my question asking if he had any patients who have been on a long-term course of Rivastigmine.
It's amazing how quickly the time has passed. We started this drug trial in January, and now it's over. We started with it to advance the body of research in the Down syndrome population. Now we have to figure out if we want to make the decision to make this about benefiting (or, possibly, damaging) Hannah. Switching from a global perspective to a personal one is going to take some time for me. We have seen positive changes in Hannah's language and memory--larger gains than we have seen before. Should we stop now? Should we see where it leads? We want to provide Hannah with every opportunity to succeed. Is this an opportunity? Or a temptation?
If you're new to this thread, I encourage you to start at the beginning. If you have a child with Down syndrome, this research study may have implications for your child. Begin here.